Technical Analysis for CRBU - Caribou Biosciences, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Very Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| NR7 | Range Contraction | -3.05% | |
| Doji - Bullish? | Reversal | -3.05% | |
| Wide Bands | Range Expansion | -3.05% | |
| Oversold Stochastic | Weakness | -3.05% | |
| New 52 Week Low | Weakness | -5.36% | |
| Stochastic Reached Oversold | Weakness | -5.36% | |
| Wide Bands | Range Expansion | -5.36% |
| Alert | Time |
|---|---|
| Down 3% | about 4 hours ago |
| Down 2 % | about 6 hours ago |
| Possible NR7 | about 6 hours ago |
| Down 1% | about 8 hours ago |
| 60 Minute Opening Range Breakdown | about 9 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 05/07/2024
Caribou Biosciences, Inc. Description
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. Caribou Biosciences has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Clinical Medicine Solid Tumors Cancer Immunotherapy Cell Therapy Cell Biology Leukemia Multiple Myeloma Breakthrough Therapy Hematologic Malignancies Chimeric Antigen Receptor T Cell T Cells CD19 Refractory Acute Myeloid Leukemia Treatment Of Relapsed Or Refractory Acute Myeloid Leukemia
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 8.5899 |
| 52 Week Low | 1.57 |
| Average Volume | 2,535,584 |
| 200-Day Moving Average | 4.76 |
| 50-Day Moving Average | 2.84 |
| 20-Day Moving Average | 1.85 |
| 10-Day Moving Average | 1.70 |
| Average True Range | 0.18 |
| RSI (14) | 25.37 |
| ADX | 53.1 |
| +DI | 11.79 |
| -DI | 33.21 |
| Chandelier Exit (Long, 3 ATRs) | 2.44 |
| Chandelier Exit (Short, 3 ATRs) | 2.11 |
| Upper Bollinger Bands | 2.21 |
| Lower Bollinger Band | 1.49 |
| Percent B (%b) | 0.14 |
| BandWidth | 39.02 |
| MACD Line | -0.36 |
| MACD Signal Line | -0.41 |
| MACD Histogram | 0.0439 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.79 | ||||
| Resistance 3 (R3) | 1.80 | 1.76 | 1.75 | ||
| Resistance 2 (R2) | 1.76 | 1.71 | 1.75 | 1.74 | |
| Resistance 1 (R1) | 1.67 | 1.68 | 1.65 | 1.66 | 1.73 |
| Pivot Point | 1.63 | 1.63 | 1.62 | 1.62 | 1.63 |
| Support 1 (S1) | 1.54 | 1.58 | 1.52 | 1.53 | 1.45 |
| Support 2 (S2) | 1.50 | 1.55 | 1.49 | 1.44 | |
| Support 3 (S3) | 1.41 | 1.50 | 1.43 | ||
| Support 4 (S4) | 1.40 |
